Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
May 16 2022 - 7:00AM
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health
innovation, today announced that Sabrina Martucci Johnson, the
company’s President and CEO, will participate in a virtual fireside
chat during the H.C. Wainwright Global Investment Conference. The
conference will be held in-person and virtually from May 23-26,
2022, with in-person participation held at the Fountainebleau Miami
Beach Hotel in Miami Beach, Florida.
Ms. Johnson’s virtual fireside chat will be
available on-demand at
https://journey.ct.events/view/2fa53f81-bd7f-404e-ad1b-20ea02738d5b
and under “Presentations, Events & Webcasts" in the Investors
section of the company's website
at http://ir.darebioscience.com, beginning at 7:00 a.m.
Eastern Time on May 24, 2022.
Following the conclusion of the conference, an
archived webcast of the fireside chat will be available on the
company’s website until June 7, 2022.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company
committed to advancing innovative products for women’s health. The
company’s mission is to identify, develop and bring to market a
diverse portfolio of differentiated therapies that prioritize
women's health and well-being, expand treatment options, and
improve outcomes, primarily in the areas of contraception,
fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATO™
(clindamycin phosphate vaginal gel, 2%), is a lincosamide
antibacterial indicated for the treatment of bacterial vaginosis in
female patients 12 years of age and older, which is under a global
license agreement with Organon. XACIATO is a clear, colorless,
viscous gel, to be administered once intravaginally as a single
dose. Daré’s portfolio also includes potential first-in-category
candidates in clinical development: Ovaprene®, a novel,
hormone-free monthly contraceptive whose U.S. commercial rights are
under a license agreement with Bayer; Sildenafil Cream, 3.6%, a
novel cream formulation of sildenafil to treat female sexual
arousal disorder utilizing the active ingredient in Viagra®; and
DARE-HRT1, a combination bio-identical estradiol and progesterone
intravaginal ring for hormone therapy following menopause. To learn
more about XACIATO™, Daré’s full portfolio of women’s health
product candidates, and Daré’s mission to deliver differentiated
therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its
finances, product and product candidates, clinical trials and other
matters using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product and product candidates, clinical
trials and other matters. The information Daré posts on its
investor relations website or through social media channels may be
deemed to be material information. Daré encourages investors, the
media, and others interested in the company to review the
information Daré posts in the Investors section of its website and
to follow these Twitter accounts: @SabrinaDareCEO and
@DareBioscience. Any updates to the list of social media channels
the company may use to communicate information will be posted in
the Investors section of Daré’s website.
Contacts:Investors on behalf of
Daré Bioscience, Inc.:Lee Roth Burns
McClellanlroth@burnsmc.com212.213.0006
OR
Media on behalf of Daré Bioscience,
Inc.:Jake RobisonCanale Communicationsjake.robison@canalecomm.com
619.849.5383
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024